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The GRCh37.p13 primary assembly of the human genome contains 20805 protein coding
mRNA, and 37147 non-protein coding genes and pseudogenes that as a result of RNA
processing and editing generate 196501 gene transcripts. Given the size and diversity of
the human transcriptome, it is timely to revisit what is known of VDR function in the
regulation and targeting of transcription. Early transcriptomic studies using microarray
approaches focused on the protein coding mRNA that were regulated by the VDR, usually
following treatment with ligand. These studies quickly established the approximate size,
and surprising diversity of the VDR transcriptome, revealing it to be highly heterogenous
and cell type and time dependent. With the discovery of microRNA, investigators
also considered VDR regulation of these non-protein coding RNA. Again, cell and time
dependency has emerged. Attempts to integrate mRNA and miRNA regulation patterns
are beginning to reveal patterns of co-regulation and interaction that allow for greater
control of mRNA expression, and the capacity to govern more complex cellular events. As
the awareness of the diversity of non-coding RNA increases, it is increasingly likely it will
be revealed that VDR actions are mediated through these molecules also. Key knowledge
gaps remain over the VDR transcriptome. The causes for the cell and type dependent
transcriptional heterogenetiy remain enigmatic. ChIP-Seq approaches have confirmed that
VDR binding choices differ very significantly by cell type, but as yet the underlying causes
distilling VDR binding choices are unclear. Similarly, it is clear that many of the VDR
binding sites are non-canonical in nature but again the mechanisms underlying these
interactions are unclear. Finally, although alternative splicing is clearly a very significant
process in cellular transcriptional control, the lack of RNA-Seq data centered on VDR
function are currently limiting the global assessment of the VDR transcriptome. VDR
focused research that complements publically available data (e.g., ENCODE Birney et al.,
2007; Birney, 2012), TCGA (Strausberg et al., 2002), GTEx (Consortium, 2013) will enable
these questions to be addressed through large-scale data integration efforts.
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THE TRANSCRIPTIONAL LANDSCAPE OF THE HUMAN
GENOME
An appreciation of the diversity of transcription across the human
genome has undergone a rapid expansion in recent years, in large
part thanks to the efforts of integrative genomic approaches such
as those of ENCODE consortium (Birney, 2012; Maher, 2012;
Stamatoyannopoulos, 2012; Rosenbloom et al., 2013). From these
studies it has become apparent that there is considerable vari-
ation and diversity in; the distribution of transcription factor
binding across the human genome; the interplay between tran-
scription factors and different co-regulating partners; the extent
of the genome that is transcribed; the number and functionally
different RNA-based molecules that are transcribed, the impact
of mechanisms that process and edit RNAmolecules that generate
even greater diversity of gene expression.
In this context it is timely to review the functions of the
vitamin D receptor (VDR/NR1I1) (Pike et al., 1980; Baker
et al., 1988; Carlberg and Campbell, 2013), and consider how
its actions contribute to this diversity of transcriptional and
post-transcriptional events.
THE VDR ACTS IN MULTIMERIC PROTEIN COMPLEXES TO
REGULATE TRANSCRIPTION
The VDR, like many other members of the nuclear receptor
superfamily are relatively well-understood transcription factors.
Their actions have been dissected and modeled, and have gener-
ated the concept of cyclical gene regulation in which transcription
factors oscillate between on and off states (Metivier et al., 2003;
Reid et al., 2003; Kim et al., 2005; Vaisanen et al., 2005; Carroll
et al., 2006; Meyer et al., 2006; Saramaki et al., 2006; Yang et al.,
2006; Zella et al., 2006; Malinen et al., 2008; Seo et al., 2007).
A direct consequence of VDR genomic interactions and gene
regulation is the control of the epigenetic states at receptor bind-
ing regions, and more broadly across target gene loci. Epigenetic
events play a central role for transcriptional complexes and the
various components in these multimeric complexes are able to
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initiate, sustain, and finally terminate transcription (Dobrzynski
and Bruggeman, 2009). For example, different histone modi-
fications can control the rate and magnitude of transcription
(reviewed in Goldberg et al., 2007). These events are inter-
twined with levels of CpG methylation (Kangaspeska et al., 2008;
Metivier et al., 2008; Le May et al., 2010). Thus the histone mod-
ifications regulated by VDR actions, and other epigenetic events
including DNAmethylation processes, combine during transcrip-
tion to generate highly flexible chromatin states that are either
transcriptionally receptive and resistant (Mohn and Schubeler,
2009). That is, the specific transcriptional potential of a gene is
flexibly controlled by the combination of epigenetic events. These
events are varied in space across the genomic loci, and in time
through the course of the transcriptional cycle.
The diversity of histone modifications, and their association
with different DNA functions formed the basis for the histone
code hypothesis. This concept, first proposed in 1993, held that
these modifications were governed in a coordinated manner and
formed a code that mirrored the underlying DNA code to convey
heritable information on transcription and expression (Turner,
1993). Given the rapid expansion of the understanding in the
number of histone modifications, their genomic distribution and
their combinatorial manner, it is only relatively recently that the
true diversity of the range of histone states, and their functional
outcomes, has become apparent (Goldberg et al., 2007). The
strongest evidence that histone modifications at the level of meta-
chromatin architecture form a stable and heritable “histone code,”
is perhaps seen with X chromosome inactivation (reviewed in
Turner, 1998). The extent to which similar processes operate to
govern the activity of micro-chromatin contexts at gene promoter
regions, is an area of debate (Jenuwein and Allis, 2001; Turner,
2002).
The regulation of transcription and the patterns of mRNA
expression have been related to the expression of these histone
modifications through a wide range of correlative and func-
tional studies. For example, histone H3 lysine 4 tri-methylation
(H3K4me3) is found in the promoter regions of actively tran-
scribed genes. This mark is mutually exclusive with H3K9me,
which instead is associated with transcriptionally silent promoter
regions. Acetylation of H3K9 is found along with methylation
of H3K4 at active promoter regions. Similarly, H3K27 can be
either acetylated or methylated, with acetylation associated with
active gene transcription and methylation associated with gene
silencing.
In many experimental cases it has been established that
VDR activation by natural ligand 1α,25-dihydroxyvitamin D3
(1α,25(OH)2D3) or synthetic analogs, can lead to a highly
dynamic exchange of co-factors by releasing co-repressors and
inducing a receptor conformation that attracts binding of co-
activator proteins (Figure 1). This exchange of associations
induces amore relaxed, or open, chromatin status and the recruit-
ment of linking factors and subsequently the basal transcriptional
machinery. However, this is not an indefinite signal and the lig-
and, is rapidly metabolized. Also the VDR itself is limited in
function by proteasome-mediated receptor degradation (Peleg
and Nguyen, 2010). In the absence of ligand, some basal level
of receptor remains in the nucleus associated with co-repressor
complex and leads to silencing of transcription (Malinen et al.,
2008; Saramaki et al., 2009; Thorne et al., 2011; Doig et al.,
2013). The sequencing, or choreography of these actions, give
rise to the periodicity of transcriptional activation and pulsatile
mRNA and protein accumulation and reflect intrinsic control
mechanisms required to tightly regulate the expression of impor-
tant signaling molecules. At closer resolution, for example on
shorter time-scales, the patterns of regulation show some degree
of coordinated pulsatile regulation, and probably reflect aspects of
specific VDR binding sites impacting gene regulation for example
through emerged to support chromatin looping within the same
VDR target gene loci (Vaisanen et al., 2005; Saramaki et al., 2006,
2009).
Whilst these scenarios are relatively well characterized for the
positive regulation of gene expression, it is probably not a com-
plete understanding as the distribution of VDR binding in the
genome (Ramagopalan et al., 2010; Heikkinen et al., 2011; Meyer
et al., 2012; Ding et al., 2013) and the patterns of associated gene
regulation suggest that the VDR is actually associated broadly
with gene activation and repression. The mechanisms that drive
gene repression appear more diverse than gene activation and
reflect differences in complex formation, and the choreography
of binding.
The patterns of protein-protein interaction identified for
the VDR allude to both positive and negative gene regulation
(Table 1). The VDR commonly forms a heterodimer with RXRα
(Quack and Carlberg, 2000). However, the identification of part-
ners that interact in the same complex supports a broad role for
the VDR complex to regulate other signal transduction events and
RNA processing activities.
A number of proteins with transcriptional activator func-
tion have been identified in complex with VDR. For example,
CBP/p300 is a transcriptional co-integrator with histone acetlyase
activity (Wang et al., 2011a,b, 2013a) and is associated with the
VDR. Other proteins such as SNW1/NCOA62 which has function
as a transcriptional co-activator(Baudino et al., 1998), as well as
other proteins that have more recently been characterized to have
coativator function (CCND3) (Cenciarelli et al., 1999; Lazaro
et al., 2002; Despouy et al., 2003; Sarruf et al., 2005). Similarly
the corepressor HR is also identified by such protein-protein
interactions (Hsieh et al., 2003).
Aside from these traditional roles to modulate transcriptional
actions, there is evidence to support a wider range of actions for
the VDR in the control of mRNA. The coactivator SNW1 also
plays a role as a splicing factor. This latter function is also shared
by another VDR interacting protein, namely SRPK1, which is a
protein kinase that regulates the activity of various splicing factors
(Hayes et al., 2006; Aubol et al., 2013). Other interactions allude
to the cross-talk between the VDR and different signal trans-
duction processes. For example, the VDR interacts with negative
regulators of WNT signaling (NKD2) (Katoh and Katoh, 2007),
substrates for PKC signaling (PRKCSH) (Gkika et al., 2004), p53
(Kommagani et al., 2006; Lambert et al., 2006; Maruyama et al.,
2006; Saramaki et al., 2006; Ellison et al., 2008) and SMAD3 (Ding
et al., 2013; Ito et al., 2013; Zerr et al., 2014). The VDR func-
tionally interacts with a range of co-repressors such as NCOR1
(Saramaki et al., 2009; Doig et al., 2013), NCOR2/SMRT (Khanim
Frontiers in Physiology | Integrative Physiology May 2014 | Volume 5 | Article 181 | 2
Campbell VDR transcriptome
FIGURE 1 | An overview of regulation and impact of the
transcriptome by the nuclear VDR and the future challenges. The
VDR toggles between a gene repressive and activating complex
depending on the presence of ligand. Ligand activated gene regulated
scenarios are most well understood. In the presense of ligand the VDR
complex is associated with both mRNA and miRNA activation and there
is clear evidence for co-regulation of these transcriptomes to tightly
control final protein coding gene expression and phenotype. Ligand
activated VDR also represses a number of miRNA for example including
those that control expression of the VDR and components of the
repressive complex. The major phenotypes associated with VDR control
include cell cycle regulation and an emerging theme is the control of the
epigenome. Four major questions remain in understanding VDR
transcription. (1) What guides where the VDR binds in the genome? (2)
What role does genetic variation in VDR binding sites play in changing
the VDR transriptome? (3) What is the total VDR transcriptome? (4)
What is the combined effect of the VDR transcriptome on health and
disease and how can this be monitored and exploited?
et al., 2004; Gynther et al., 2011), TRIP15/ALIEN (Polly et al.,
2000; Cui et al., 2009) and DREAM (Scsucova et al., 2005) but,
interestingly, agnostic protein-protein interaction tools such as
INTACT (Table 1) have not identified direct VDR co-repressor
interactions. It is unclear why these proteins are not identified
in such protein-protein screens, but may reflect an experimental
artifact as a result of investigators using ligand stimulated VDR to
capture interacting proteins.
THE DIVERSITY OF VDR-PROTEIN INTERACTIONS IS REFLECTED BY
THE DISTRIBUTIONS OF GENOMIC BINDING SITES
To identify VDR binding sites through the genome several groups
have now applied ChIP-Seq approaches in different human cell
types including immortalized lymphoblastoids (Ramagopalan
et al., 2010), hepatic stellate cells (Ding et al., 2013) and cancer cell
lines representing monocytic leukemia (Heikkinen et al., 2011)
and colon cancer (Meyer et al., 2012). These studies also dif-
fered in the time of cell exposure to 1α,25 (OH)2D3 ranging from
40min to 36 h identify binding sites, on the order of hundreds to
several thousands of different binding sites depending on time of
treatment with 1α25(OH)2D3 and cell background, with longer
treatment time points tending to be associated with more bind-
ing sites. However, as yet there are not uniform standards for the
analyses of NGS data, and therefore it is likely that different ana-
lytical approaches are influencing the number and significance of
the VDR enriched peaks identified.
These differences in treatment and analytical approaches aside,
these VDR binding data sets reveals that fewer than 20% of the
VDR binding sites are in common between the different cell types.
These finding perhaps offers strong support for the concept that
VDR transcription is extremely tailored in different cell types,
presumably through interactions with either equal or more dom-
inant co-factors that combine to determine its binding. Another
important finding from these studies is that the canonical bind-
ing site for the VDR, termed the direct repeat (DR) spaced by
3 nucleotides (DR-3), which was identified by traditional bio-
chemical approaches in candidate gene studies, appears to be
the minority genomic element that directly binds the receptor.
Fewer that 30% of genomic VDR binding sites contain a DR-
3, although this number is increased following ligand treatment
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Table 1 | Proteins known to interact with the VDR.
Interacting protein Function Detection method Interaction Publication
Retinoid X receptor alpha (RXRα) Transcription factor Electron microscopy Direct interaction Orlov et al., 2012
Retinoid X receptor beta (RXRβ) Transcription factor Two hybrid Physical association Wang et al., 2011a
E1A-associated protein p300
(CBP/p300)
Histone acetyltransferase Two hybrid Physical association Wang et al., 2011a
Mediator complex subunit
(MED1)
Mediator complex that binds basal
transcriptional machinery and
drives transcriptional initiation
Pull down Physical association Yuan et al., 1998
Nuclear receptor coactivator 6
(NCOA6)
Transcriptional coactivator of
multiple nuclear receptors and
other transcription factors
Two hybrid Physical association Mahajan and Samuels,
2000
CXXC-type zinc finger protein 5
(CXXC5)
Transcription factor co-regulator of
WNT signaling
Two hybrid Physical association Wang et al., 2011a
Tumor Protein P53 (p53) Tumor suppressor protein
containing transcriptional
activation, DNA binding, and
oligomerization domains
Fluorescence
microscopy
Co-localization Stambolsky et al., 2010
Protein naked cuticle homolog 2
(NKD2)
Antagonist of WNT via degradation
DVL
Two hybrid Physical association Wang et al., 2011a
SMAD family member 3
(SMAD3)
Transcriptional effector of TGFβ Pull down Physical association Leong et al., 2001
SNW Domain containing
1(SNW1)
Co-activator function with known
roles as a splicing factor
Two hybrid Physical association and
co-localization
Baudino et al., 1998;
Zhang et al., 2003
SFRS protein kinase 1 (SRPK1) Serine/arginine protein kinase
specific for the SR
(serine/arginine-rich domain) family
of splicing factors
Protein kinase assay Phosphorylation reaction Varjosalo et al., 2013
Protein kinase C substrate 80
K-H (PRKCSH)
Substrate for protein kinase C Two hybrid Physical association Wang et al., 2011a
Protein-tyrosine phosphatase
H1(PTPN3)
Protein tyrosine phosphatase that
regulate a variety of cellular
processes
Pull down Physical association Zhi et al., 2011
Complement Factor H (CFH) Regulator of complement
activation (RCA) gene cluster and
plays a role in the defense
mechanism to microbial infections
Two hybrid Physical association Wang et al., 2011a
β-catenin Dual function protein, regulating
the coordination of cell–cell
adhesion and gene transcription.
Co-localization Functional interaction Pálmer et al., 2001
Prolylcarboxypeptidase
(Angiotensinase C) (PRCP)
A lysosomal
prolylcarboxypeptidase, which
cleaves C-terminal amino acids
linked to proline
Two hybrid Physical association Wang et al., 2011a
Cyclin D3 (CCND3) Cyclin associated with control of
cell cycle and known co-factor for
several nuclear receptods
Two hybrid Physical association Wang et al., 2011a
(Continued)
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Table 1 | Continued
Interacting protein Function Detection method Interaction Publication
Hair growth associated (HR) Transcriptional corepressor of
multiple nuclear receptors
Pull down Direct interaction Hsieh et al., 2003
Nuclear corepressor 1 (NCOR1) Transcriptional corepressor Two hybrid Physical association Tagami et al., 1998
Nuclear corepressor 2 (NCOR2) Transcriptional corepressor Immunoprecipitation Physical association Kim et al., 2009
COP9 signalosome subunit 2
(COPS2)
Transcriptional corepressor and
component of the ubiquitin
conjugation pathway
Two hybrid Physical association Polly et al., 2000
The INTACT database curated by EBI http://www.ebi.ac.uk/intact/ was interrogated for interactions with the VDR. Interactions of VDR with NCOR1, NCOR2, and
COPS2 were curated from the literature.
when there is increased enrichment for VDR binding to DR-3 ele-
ments (reviewed in Carlberg and Campbell, 2013). Nonetheless,
a range of other genomic elements were enriched in VDR bind-
ing peaks suggesting that the VDR co-operates closely with other
factors to associate with the genome, both in the absence and
presence of ligand. Indeed, the study of Evans and co-workers
in the hepatic stellate cells (Ding et al., 2013) and the work of
Pike and co-workers in colon cancer cells (Meyer et al., 2012)
both address this significant cross-talk of the VDR. In the case
of the hepatic cells this is considered in the context of TGF® and
in the case of colon cancer cells this is with TCF4, downstream
of ®-catenin. Both of these studies therefore reflect the finding of
VDR interactions with SMAD3 specifically, and more generally
with regulators of WNT signaling (Table 1).
THE HUNT FOR PIONEER FACTORS TO EXPLAIN THE DIVERSITY OF VDR
FUNCTION
Together these ChIP-Seq studies suggest that the VDR combines
with other proteins in a network of interactions, quite likely in a
cell type specific manner, to participate in diverse gene regulatory
networks. It remains to be established how targeted or stochas-
tic this is. The variation observed in both the type and position
of binding sites for the VDR, depending on cell phenotype and
disease state, suggests it is directed, and at least will establish a
paradigm for hypothesis testing concerning what directs the VDR
to bind and participate in gene transcription. The specificity of
VDR signaling may arise due to integration with other perhaps
more dominant transcription factors. Again, for other nuclear
receptors (e.g., AR and ER) the concept has emerged that recep-
tor binding is guided by the actions of more dominant so-called
pioneer factors including the Forkhead (FKH) family members
(Lupien et al., 2008; Serandour et al., 2011; Sahu et al., 2013).
Efforts to define the major pioneer factors for the VDR have
proved to be less consistent between the different VDR ChIP-Seq
studies and may reflect the biology of the VDR which, given that
it exists in the nucleus both in the presence and absence of lig-
and, potentially is a more interactive protein such that a single
dominant pioneer factor is not so deterministic.
Another approach to identify the interacting partners of
the VDR has been to examine the gene networks it regulates
and to cluster genes by known regulating transcription factors.
Novershtern et al. (2011) measured the transcriptome profiles of
a large number of hematopoietic stem cells, multiple progenitor
states and terminally differentiated cell types. They found dis-
tinct regulatory circuits in both stem cells and differentiated cells,
which implicated dozens of new regulators in hematopoiesis.
They identified 80 distinct modules of tightly co-expressed genes
in the hematopoietic system. One of these modules is expressed
in granulocytes and monocytes and includes genes encoding
enzymes and cytokine receptors that are essential for inflamma-
tory responses. Major players in this module are VDR together
with the factors CEBPα and SPI1/PU.1. This indicates that VDR
works together with this small set of transcription factors, in order
to regulate granulocyte andmonocyte differentiation. It is reason-
able to anticipate that suchmodules exist inmultiple cell types but
are guided by the tissue specific expression of such factors.
VDR REGULATION OF THE PROTEIN-CODING TRANSCRIPTOME
Anti-proliferative effects of 1α,25(OH)2D3 have been demon-
strated in a wide variety of cancer cell lines, including those
from prostate, breast, and colon (Colston et al., 1982, 1989; Peehl
et al., 1994; Campbell et al., 1997; Koike et al., 1997; Elstner
et al., 1999; Welsh et al., 2002; Pálmer et al., 2003). Following
on from these, VDR transcriptional studies were initially under-
taken at the candidate level to identify processes by which the
VDR mediated its cellular effects. These approaches identified
of the gene encoding the 1α,25(OH)2D3 metabolizing enzyme
CYP24A1 (Dwivedi et al., 2000; Anderson et al., 2003) and
CDKN1A (encodes p21(waf1/cip1)) (Schwaller et al., 1995) as VDR
targets. Subsequently, with the emergence of differential expres-
sion and membrane array technology, workers applied these
wider screening approaches to identify multiple genes regulated
by the VDR. For example, Freedman and colleagues applied dif-
ferential expression approaches in the context of 1α,25(OH)2D3
induced myeloid differentiation and identified a number of cyclin
dependent kinase inhibitors including CDKN1A and undertook
functional confirmation studies to suggest the importance of the
regulation of these targets to trigger myeloid differentiation (Liu
et al., 1996). Others undertook so-called focused array technology
whereby cDNA probes for selected genes involved in key bio-
logical processes or disease states were arranged on macro scale
membrane arrays. Such arrays contained anywhere from several
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hundred to several thousand probes, and so were not genome-
wide in terms of coverage but rather were candidate arrays often
focused around specific pathways or disease states such as can-
cer. Despite the limitations, these approaches yielded important
information supporting the links between VDR action and the
regulation of growth and signaling (Savli et al., 2002). Similarly,
first generation arrays chips, for example from Affymetrix which
contained 4500 probes (Akutsu et al., 2001), also enabled suf-
ficient genomic coverage to begin to define specific regulated
gene networks. This particular study from White (Akutsu et al.,
2001) and co-workers identified 38 genes that were responsive to
1α,25(OH)2D3 exposure, which represented approximately 1% of
the transcriptome studied, and includedGADD45A. These earlier
studies already suggested at the footprint of the VDR dependent
transcriptome (reviewed in Rid et al., 2013). In many ways these
studies highlighted the heterogeneity of VDR actions that was to
be identified subsequently by ChIP-Seq studies. This heterogene-
ity may in part reflect experimental conditions with very different
cell line differences, and genuine tissue-specific differences of co-
factor expression that alter the amplitude and periodicity of VDR
transcriptional actions.
Even within this diversity there is some consistency on a certain
targets and the biological actions they relate to, including cell cycle
regulation (Akutsu et al., 2001; Pálmer et al., 2003; Eelen et al.,
2004; Wang et al., 2005). A common anti-proliferative VDR func-
tion is associated with arrest at G0/G1 of the cell cycle, coupled
with up-regulation of a number of cell cycle inhibitors. Candidate
promoter characterization studies have demonstrated a series of
VDR binding sites in the promoter/enhancer region of CDKN1A
(Liu et al., 1996; Saramaki et al., 2006). By contrast the regulation
of the related CDKI p27(kip1) is mechanistically enigmatic, and
included translational regulation and enhanced mRNA transla-
tion, and attenuating degrading mechanisms (Hengst and Reed,
1996; Wang et al., 1996; Huang et al., 2004; Li et al., 2004). The
up-regulation of p21(waf1/cip1) and p27(kip1) principally mediate
G1 cell cycle arrest, but 1α,25(OH)2D3 has been shown to medi-
ate a G2/M cell cycle arrest in a number of cancer cell lines via
direct induction of GADD45A (Akutsu et al., 2001; Jiang et al.,
2003; Khanim et al., 2004).
In the transition to genome wide understanding, workers
applied more comprehensive array approaches to define VDR
mRNA transcriptomes. For example, investigations of squa-
mous cells (Lin et al., 2002; Wang et al., 2005) identified net-
works of genes that trigger the response to wounding, protease
inhibition, secondary metabolite biosynthesis, cellular migra-
tion, and amine biosynthetic processes. Another approach has
been to examine vitamin D sensitive and responsive isogenic
cell pairs and undertake analyses to identify key networks that
are critical for mediating antiproliferative sensitivity toward
1α25(OH)2D3. In this manner a critical role for TGF® sig-
naling was again revealed, to associate with VDR antiprolif-
erative sensitivity toward 1α25(OH)2D3 in breast cancer cell
models (Towsend et al., 2006). Exploiting leukemia cell models
with differential responsiveness toward 1α25(OH)2D3 triggered-
differentiation (Tagliafico et al., 2006) identified that certain VDR
transcriptional targets could distinguish the aggressiveness of the
leukemia, again, focused around cell cycle and included MS4A3
which can modulate the phosphorylation of CDK2 and therefore
exert control over the cell cycle. This concept of VDR sensi-
tive vs. resistant models was also exploited in prostate cancer
to identify the critical VDR transcriptional targets that medi-
ate antiproliferative sensitivity and again also identified cell cycle
and signal transduction components including GADD45A and
MAPKAPK2 that were required to mediate the sensitivity of cells
to 1α,25(OH)2D3. Furthermore, these studies examined the epi-
genetic basis for the transcriptionally inert state of these targets in
resistant models (Rashid et al., 2001; Khanim et al., 2004).
Identification of the VDR-dependent transcriptome using
microarray approaches is heavily dependent on a range of statisti-
cal and technical considerations (Do and Choi, 2006; Zhang et al.,
2009) including hybridization variations and limitations, back-
ground effects, normalization procedures, the choice of statistical
test to identify differentially expressed genes, which in turn relies
on study design and the numbers of arrays and samples chosen
for study. Many of these study components were only formally
agreed upon with the establishment of the MIAME compliant
protocols in 2001 (Brazma et al., 2001), and as these became
accepted standards for journal publication these approaches
became widespread through the biological community.
MIAME compliant array experiments are subsequently pub-
lished in public archives, such as GEO (Barrett et al., 2005, 2013)
and ArrayExpress at EMBL (Parkinson et al., 2007) and Stanford
microarray database (Marinelli et al., 2008). These three reposi-
tories between them contain thousands of genome-wide microar-
ray experiments, containing millions of individual microarrays.
Mining these repositories reveals a range of experiments (not all
published) where cells have been treated with 1α,25(OH)2D3 and
other vitamin D compounds, and RNA effects studied between
short time points (1–2 h) to several days (Table 2). Again, these
studies have supported consistent themes in terms of the VDR-
mediated control of cell cycle and signal transduction processes,
the suppression of WNT and NF-κB, and the regulation of IGF1
signaling (Kovalenko et al., 2011), and integrated actions with
TGF® signaling. A final area to emerge from these agnostic stud-
ies of the VDR transcriptome is the impact that 1α25(OH)2D3
exposure exerts on a range of chromatin remodeling components.
Interestingly, NCOR2/SMRT appears to be a target of VDR sig-
naling (Dunlop et al., 2004), and adds to the concept that VDR
signaling is cyclical and based on the functions of various negative
feedback loops. Similarly, KDM6B/JMJD3 is a histone H3 lysine
demethylase and expression is induced by the activated VDR. In
this manner, VDR action can feed-forward its own transcriptional
program by promotingH3K9 acetylation and gene action (Pereira
et al., 2011).
Given the number of arrays available, it is now timely to con-
sider meta-analyses across the arrays to reveal common themes;
this forward compatibility is one the key benefits of MIAME com-
pliance. Meta-integration of array data has been shown to be
surprisingly revealing in a range of studies. For example at the
larger scale various workers have integrated multiple microar-
ray data to reveal underlying patterns in the context of disease
classification (Shah et al., 2009; Engreitz et al., 2011) but can
also be applied to consider that specific phenotypes (Martinez-
Climent et al., 2010; Rantala et al., 2010; Lai et al., 2014). It is
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Table 2 | Publically available MIAME compliant microarray studies of VDR function.
Experimental title/design GEO series accession Publication
number
PROTEIN CODING MRNA
Vitamin D effect on bronchial smooth muscle cells GSE5145 Bosse et al., 2007
Genome-wide analysis of vitamin D receptor (VDR) target genes in THP-1 monocytic leucemia
cells
GSE27270 Heikkinen et al., 2011
Transcriptional effects of 1,25 dihydroxi-vitamin D3 physiological and supra-physiological
concentrations in breast cancer organotypic culture
GSE27220
Analysis of vitamin D response element binding protein target genes reveals a role for vitamin
D in osteoblast mTOR signaling
GSE22523 Lisse et al., 2011
Expression profiling of androgen receptor and vitamin D receptor mediated signaling in
prostate cancer cells
GSE17461 Wang et al., 2011b
Understanding vitamin D resistance using expression microarrays GSE9867 Costa et al., 2009
Effects of TX527, a hypocalcemic vitamin D analog on human activated T lymphocytes GSE23984 Baeke et al., 2011
Transcriptome profiling of genes regulated by RXR and its partners in monocyte-derived
dendritic cells
GSE23073 Szeles et al., 2010
NON-PROTEIN CODING RNA
MicroRNA-22 upregulation by vitamin D mediates its protective action against colon cancer. GSE34564 Alvarez-Diaz et al., 2012
miRNA profiling of androgen receptor and vitamin D receptor mediated signaling in prostate
cancer cells
GSE23814 Wang et al., 2013b
Identification of miRNAs regulated by vitamin D within primary human osteoblasts GSE34144
Vitamin D and microRNA expression GSE20122
therefore timely for these data to mined, and integrated with
related nuclear receptor actions or other transcription factors that
appear to co-operate with the VDR, for example SMADs.
VDR REGULATION OF NON-CODING RNA SPECIES
The human genome project in many ways was a race to define the
protein coding genes within the human genome. Bacterial artifi-
cial chromosomes (BAC) clones enabled relatively large pieces of
DNA, upto 300 kb to be inserted for sequencing (Osoegawa et al.,
2000). However, a key step in the initial alignment process was to
leverage cDNA and EST libraries and therefore naturally steered
workers to protein coding genes, and the significance and extent
of non-protein coding RNA remained largely unexplored.
Although non-coding RNA forms were well described in
terms of ribosomal function it was little understood beyond this.
The interpretation of the human genome, and other large scale
approaches to investigating chromosomal function (Consortium
et al., 2007; Tress et al., 2007) all led to a growing awareness
of the extent of non-coding RNA and at least suggested that
their was an unknown. This uncertainty has been reflected in
the debate within the biological community over the extent
and roles of so-called Junk DNA (Kapranov and St Laurent,
2012; Doolittle, 2013). As a result researchers have considered
roles for non-coding RNA in the regulation of cell function
and have begun to examine the interplay between the at least
20 different types of different non-coding RNA (reviewed in
Ling et al., 2013). Many of these RNA species are gene regu-
latory RNA and include microRNA (miRNA), long non-coding
RNA (long ncRNA), whereas others are involved in the post-
transcriptional modification of RNA for example small nucleolar
RNA (snoRNA).
Workers have now principally examined miRNA regulation
by the VDR and evidence has emerged to support a role for
the VDR to control regulation. For example Studzinski and co-
workers revisited the mechanistically enigmatic VDR-mediated
control p27(kip1). They elegantly demonstrated a role for VDR
to down-regulate miR181a, which when left unchecked degrades
p27(kip1)(Wang et al., 2009) (Figure 1). Thus, indirectly, VDR
activation elevates expression of p27(kip1), initiates cell cycle arrest
and commits cells toward differentiation. These studies illumi-
nated the earlier ones that suggested that p27(kip1) protein levels
appeared to be regulated by a range of post-transcriptional mech-
anisms, such as enhanced mRNA translation, and attenuating
degradative mechanisms (Hengst and Reed, 1996; Huang et al.,
2004; Li et al., 2004). Similar integration of miRNA and mRNA
was revealed to control the regulation of CDKN1A. Dynamic
patterns of CDKN1A mRNA accumulation have been observed
in various cell systems (Thorne et al., 2011). This is in part
explained by the epigenetic state of different VDR binding sites on
the CDKN1A promoter. However, VDR-dependent co-regulation
of miR-106b also appears to modulate the precise timing of
CDKN1A accumulation and expression of p21(waf1/cip1) in a feed-
forward loop and determine the final extent of the cell cycle arrest.
1α,25(OH)2D3 regulates the DNA helicaseMCM7 (Khanim et al.,
2004) that encodes themiR-106b, in intron 13 of theMCM7 gene,
and together these co-regulation processes control p21(waf1/cip1)
through the balance of MCM7 and CDKN1A (Saramaki et al.,
2006; Ivanovska et al., 2008) (Figure 1).
MicroRNA (miRNA) contribute negative regulatory aspects
to normal gene regulation, for example as part of feed-forward
loop motifs (Mangan and Alon, 2003; Mangan et al., 2006).
The co-regulation of mRNA and miRNA in motifs that included
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feed forward structures appears quite common (Song and Wang,
2008; Gatfield et al., 2009; Ribas et al., 2009; Sun et al., 2009;
Wang et al., 2009). Other established miRNA targets of the VDR
include miR-627 (Padi et al., 2013) that in turn targets JMJD1A
(another histone H3 lysine demethylase) miR-98 (Ting et al.,
2013) and let-7a-2 (Guan et al., 2013). However, one of the more
explored relationships between VDR and miRNA is the rela-
tionship between VDR and miR-125b. MiR-125b inhibits VDR
(Mohri et al., 2009; Zhang et al., 2011) and in turn VDR can
down-regulate miR-125b (Iosue et al., 2013; Zhou et al., 2014),
and the other targets of miR-125b include NCOR2/SMRT (Yang
et al., 2012) (itself a VDR target gene) suggestingmultiple levels of
co-regulation and interdependent relationship between the VDR,
and the mRNA and miRNA transcriptomes, and the epigenome.
Finally, it is interesting to note that altered levels of miRNA are
associated with cancer states and progression risks and indeed
miR-125b is associated with aggressive prostate cancer (Shi et al.,
2011; Amir et al., 2013; Singh et al., 2014).
Beyond these candidate studies, a number of investigators
have undertaken miRNA microarray analyses (Table 2) and these
approaches have identified various networks, including the con-
trol of lipid metabolism and PPAR© function (Wang et al.,
2013b). It is likely that with the increased application of array
approaches and next gen sequencing approaches will identify
the key networks downstream of the VDR miRnome. This is
unfortunately a more challenging research question owing to the
many-to-many nature of miRNA; a given miRNA target many
mRNA, and a given mRNA may have many miRNA targeting
it. Thus, the computational challenges to resolve these relation-
ships are not insignificant. Together these findings suggest that
co-regulated miRNA may form an integral part of VDR signaling
to control gene expression.
Of the other types of non-coding RNA, their regulation by
VDR remains far less explored. Recently the group of Bickle have
begun to dissect VDR regulation of lncRNA in keratinocytes and
identified a number of target lncRNA and in doing so have raised
the curtain on new avenues of exploration (Jiang and Bikle, 2014).
CONCLUSIONS AND FUTURE CHALLENGES FOR
UNDERSTANDING THE VDR TRANSCRIPTOME
WHAT ARE THE PROTEINS, OR PROCESSES THAT GUIDE WHERE THE
VDR BINDS IN THE GENOME?
It is unclear what key pioneer factors will be identified and if the
VDR is in a strong relationship with a specific family of pioneer
factors, in the same that the AR is profoundly influenced by the
Forkhead family members. Indeed, the precise pioneer factor may
even be tissue specific as also revealed for the AR (Pihlajamaa
et al., 2014). This may reflect the fact the ligand activation of the
VDR is more associated with re-distribution of the VDR through
the genome, rather than triggeringmovement into the nucleus (as
in the case of the classic steroid hormone receptors).
The specific epigenetic niche that characterizes the VDR bind-
ing may also be revealing of where and why the VDR binds to
the genome. These analyses will require agnostic integration of
multiple genomic data sets, for example histone modifications,
transcription factor binding, chromatin conformation and tran-
scriptomic data and application of machine learning approaches
to reveal the significance of the underlying patterns, VDR bind-
ing and transcriptional activity. Whilst the VDR was not included
in the ENCODE project, judicious choice of a cell line model for
these studies, most likely a Tier 1 cell line from ENCODE, will
enable leverage of a considerable volume of cistromic and epige-
nomic data to be combined with de novo VDR ChIP-Seq data.
In this manner the question of how TGF® and/or WNT signaling
interacts directly or indirectly with VDR binding can be addressed
relatively easily.
Another major knowledge gap in VDR understanding con-
cerns the spatial relationships between VDR binding and the
control of transcription. It is clear that chromatin looping pro-
cesses can transiently bring distal regulatory regions into physical
proximity to the proximal regions of a gene and lead to dynamic
gene expression (Saramaki et al., 2009). To transition from exami-
nation of looping of this process at a single locus using established
binding sites to the genome wide investigation is technically and
statistically very challenging. Again, ENCODE analyses may be
useful here, as Chromatin Interaction Analysis by Paired-End Tag
Sequencing (ChIA-PET) data are available for specific cell lines;
for example using RNA-PolII in K562 cells and therefore VDR
ChIP-Seq in these cells would again be able to leverage this data
to begin to understand how the VDR distributes and loops across
the genome.
WHAT IS THE ROLE OF GENETIC VARIATION IN DETERMINING HOW
ANDWHERE THE VDR BINDS?
Genetic variation exists throughout the genome and by defini-
tion is predominately in non-RNA coding regions. This realiza-
tion has been the catalyst for examining how genetic variation
impacts transcription factor binding and activity. Perhaps the
most comprehensive integration of these concepts has been the
development of the RegulomeDB tool (Boyle et al., 2012) which
considers the impact of genetic variation on the function of all
transcription factors analyzed by ENCODE. To date this ques-
tion has not been seriously considered in terms of the VDR. A
major hurdle to addressing this question is very large potential
for Type 1 error owing to the large-scale data sets that need to be
integrated, namely; all SNPs and those in linkeage disequilibrium
that are significantly associated with disease in replicated studies
and all binding sites for a given transcription factor against the
backdrop of the number of SNPs for a given trait, the platform
used for identification and the total number of SNPs in the human
genome. In the context of the VDR specifically, this challenge is
compounded by the fact that the majority of VDR binding sites
through the genome do not contain a canonical DR3 type bind-
ing element and therefore a critical question will remain around
what protein is the VDR interacting with in the genomic context
and how is this influenced by genetic variation. This challenge is
clearly intertwined with developing a comprehensive knowledge
of how the VDR binds to the genome.
WHAT IS THE COMPLETE VDR TRANSCRIPTOME AND HOW DOES IT
DIFFER BY TISSUE AND BY DISEASE?
Surprisingly, no RNA-Seq data are yet available for the VDR.
Therefore to capture all RNA regulated by the VDR will require
RNA-Seq approaches applied to libraries that capture short and
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long RNA species. The ENCODE consortium have undertaken
over 400 RNA-Seq experiments focused on different RNA species
in multiple cell models, and this makes a compelling case for
exploiting these data, especially in Tier 1 or Tier 2 cell lines.
For example undertaking VDR ChIP-Seq and a limited num-
ber of RNA-Seq approaches in K562 cells has the potential to
leverage a remarkable volume of data. Predictions from such inte-
grative analyses could then be tested in other ENCODE resources,
in RNA-Seq from multiple tissues in normal healthy donors,
through the GTEx consortium, or through the vast numbers of
microarrays that are publically available. For example, in the case
of K562, which is a CML cell line, there are many large-scale
microarray analyses of patients with CML to examine how the
VDR transcriptome relates to disease state and drug response. A
parallel outcome of investigating VDR function will be to address
the role it plays in regulating splice variation as suggested by the
interactions with proteins such as SNW1.
HOWWILL THIS KNOWLEDGE BE EXPLOITED IN PERSONALIZED
MEASURES OF VDR SYSTEM IN HEALTH AND DISEASE?
Many aspects of the relationships identified above can be inter-
preted by serum borne measurements, which are highly attractive
owing to their ease of measurement. Serum levels of the pro-
hormone, 25(OH) vitamin D3, are strongly correlated with the
generation of the active hormone 1α,25(OH)2D3 and VDR func-
tion. For example, reduced serum levels of 25(OH) vitamin D3
levels are associated with increased risk of either cancer initia-
tion and/or progression (Drake et al., 2010; Shanafelt et al., 2011).
Therefore the serum level of 25(OH) vitamin D3can yield the
“potential” of the VDR system to signal (Brader et al., 2014). This
potential is impacted by the various cellular mechanisms out-
lined above. Of these, genetic variation that impacts VDR binding
can obviously be measured in any cell in the body. The total
transcriptome can be challenging to measure but perhaps small
non-coding RNA represent a highly attractive marker of activ-
ity. Remarkably, miRNA are readily secreted into serum where
they remain stable (El-Hefnawy et al., 2004; Goyal et al., 2006;
Taylor and Gercel-Taylor, 2008; Valadi et al., 2007) and can be
reliably extracted and measured (Chen et al., 2008; Liu et al.,
2008; Mitchell et al., 2008; Rabinowits et al., 2009). Using serum-
borne molecules as prognostic markers is highly attractive for
several reasons. First, they can overcome the limitations of inac-
curate sampling for example in the case of the presence of cancer
within a tumor biopsy. Second, they can encapsulate the effects
of heterotypic cell interactions, again, for example within the
tumor microenvironment. Third, they form a non-invasive test
procedure. From a biostatistical perspective, given there are fewer
miRNA than protein coding mRNA, genome-wide coverage is
more readily achieved and avoids the statistical penalties typically
associated mRNA genome wide testing (Lussier et al., 2012).
This raises the very exciting possibility that generating inte-
grated models of VDR binding, the impact of genetic variation,
the tissue specific differences in the transcriptome and identify-
ing miRNA contained within transcriptional circuits offers the
opportunity of exploiting their serum expression levels of 25(OH)
vitamin D3, genetic variation and miRNA expression will be able
to be exploited to predict accurately the capacity of VDR function.
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